

Supplementary Materials:




Figure S1. The expression profiles of *AntiCabs1* in mice and humans. (A) *AntiCabs1* exclusively expressed in mouse testis. (B) *AntiCabs1* expression in mouse testis at different stages of development. (C) *AntiCabs1* expression in human tissues. Total RNA was isolated from mouse tissue samples using a RNAiso Plus kit, and human tissue RNAs were purchased from Takara (Dalian, China). RT-PCR was performed to detect the *AntiCabs1* expression level. The β -actin gene was used as a loading control.




Figure S2. Generation of *AntiCabs1* KO mice. (A) The diagrams of the targeting strategy and genotyping primer sites. (B) Validation of the *AntiCabs1* KO mouse model. PCR genotyping was performed on tail genomic DNA with the two primer sets, allowing for the specific recognition of WT (760 bp) and KO (498 bp) alleles. (C) Schematic representation of *AntiCabs1*-specific RT-PCR primer. (D) Investigation of *AntiCabs1* expression in *AntiCabs1* KO mice. Total RNA extracts from the testis were used to confirm the absence of *AntiCabs1* transcripts (950 and 280 bp PCR products) by RT-PCR with specific two primer sets in KO mice.




Figure S3. Testicular and epididymal phenotypes in *AntiCabs1* KO mice. (A) Histological analyses of the testis and epididymis sections from WT and *AntiCabs1* KO mice stained with hematoxylin and eosin. (B) Testis weight. The weight of the testis and body was weighed by an electronic balance. (C) Sperm concentration and (D) motility in male WT and KO mice were measured by computer-assisted sperm analysis (CASA) using the sperm collected from the cauda epididymitis. (E) Male fertility and (F) litter size. Pregnancy and litter size were counted in mating cages with male WT and KO mice over a period of 3 months.




Figure S4. *Cabs1* expression is independent on *AntiCabs1*. (A) *Cabs1* and *AntiCabs1* overexpression of the H293 cell lines were constructed by transfecting the Enhanced Green Fluorescent Protein (EGFP)-labeled lentiviral vectors, pLV-*Cabs1* and pLV-*AntiCabs1*, respectively. (B) Confirmation of *Cabs1* and *AntiCabs1* overexpression of the H293 cell lines. The cells that overexpressed *AntiCabs1* and *Cabs1* were used to isolate the total RNA, and then, RT-PCR was performed to amplify the *Cabs1* and *AntiCabs1* transcripts. (C) Effect of *AntiCabs1* on *Cabs1* protein expression in vitro. *Cabs1* expression levels were detected by Western blot after the *Cabs1* overexpressed cells were treated with the *AntiCabs1* lentiviral vector for 60, 72, or 96 h. (D,E) Effect of *AntiCabs1* on *Cabs1* mRNA and protein expressions in vivo. *Cabs1* mRNA expression levels were detected by qPCR. *Cabs1* protein expression levels were determined by Western blot in *AntiCabs1* homozygous, heterozygous, and WT mice. Gapdh and β -actin were used as loading controls.




Figure S5. The generation and confirmation of *Cabs1* KO mice. **(A)** Three-line KO founder mice were produced. **(B)** Amino acid sequences encoded by wild-type and mutant *Cabs1*. **(C,D)** Sanger sequencing of *Cabs1* WT and KO alleles.




Figure S6. Schematic diagram of *Cabs1* **(A)** and *AntiCabs1* **(B)** lentivirus gene expression vectors. Vectors were constructed and packed by Cyagen US Inc. (Guangzhou, China).

Table S1. The primer sequences of the examined genes.

Purpose	Sym-bol/ID	Forward Primer	Reverse Primer	Length(bp)
Genotyping primers	Cabs1	TGGTGAGCCCCTGTCATTACCTG	AACAGCTCCATCATCAGGAGCATC	756
Sequencing Primers	Cabs1	CAATGCTTCAGTCACTATTCTGG		
qPCR	Cabs1	AGGTCACCACCATTCCAGACA	AGTGAGCAGAACAGCATGGG	257
PCR_CDS	Cabs1	ATGGCTGAAGATGGATCGC	TTACATCATGAGATCGTCTGGTTC	1176
Genotyping primers_KO	AntiCabs1	TGTGAACACCACAGATTTGCCTGA	AGTCTATTTACACCCACAC-TCCCTCTCA	760
Genotyping primers_WT	AntiCabs1	GAAATGGCTTCCTTTACTGCTT-GCC	AGTCTATTTACACCCACAC-TCCCTCTCA	498
qPCR	AntiCabs1	GGGATGAGGTGTGAGCTTGT	GGGCTGACAACACCATTCTCTA	128
specific1_PCR	AntiCabs1	AATGCCCAATATTCTTTTTTCT	AACAAGCTCACACCTCATCC	950
specific2_PCR	AntiCabs1	TGGGGATGAGGTGTGAGC	TTGCCAGGGATGCCACT	280
PCR	AntiCabs1	AATGCCCAATATTCTTTTTTCT	CTTGCCAGGGATGCCACT	1208
qPCR	Ccny1	TGGACATTTTGTGATGAGCGGT	ACCAACGTCACTATTGCACATTC	157
qPCR	Sept4	ACGGAATCGCAACAACACTGAC	TCTTCTCCCGGATTAGCTTCTC	104
qPCR	Krt1	TGGGAGATTTTCAGGAGGAGG	GCCACACTCTTGAGATGCTC	104
loading control	β -actin	GGCTGTATCCCCTCCATCG	CCAGTTGGTAAACAATGCCATGT	154